1. Home
  2. HOND vs LUNG Comparison

HOND vs LUNG Comparison

Compare HOND & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOND
  • LUNG
  • Stock Information
  • Founded
  • HOND 2024
  • LUNG 1995
  • Country
  • HOND United States
  • LUNG United States
  • Employees
  • HOND N/A
  • LUNG N/A
  • Industry
  • HOND
  • LUNG Industrial Specialties
  • Sector
  • HOND
  • LUNG Health Care
  • Exchange
  • HOND NYSE
  • LUNG Nasdaq
  • Market Cap
  • HOND 334.9M
  • LUNG 124.0M
  • IPO Year
  • HOND 2024
  • LUNG 2020
  • Fundamental
  • Price
  • HOND $11.14
  • LUNG $2.75
  • Analyst Decision
  • HOND
  • LUNG Buy
  • Analyst Count
  • HOND 0
  • LUNG 6
  • Target Price
  • HOND N/A
  • LUNG $11.53
  • AVG Volume (30 Days)
  • HOND 328.4K
  • LUNG 322.4K
  • Earning Date
  • HOND 01-01-0001
  • LUNG 07-30-2025
  • Dividend Yield
  • HOND N/A
  • LUNG N/A
  • EPS Growth
  • HOND N/A
  • LUNG N/A
  • EPS
  • HOND 0.20
  • LUNG N/A
  • Revenue
  • HOND N/A
  • LUNG $87,473,000.00
  • Revenue This Year
  • HOND N/A
  • LUNG $18.02
  • Revenue Next Year
  • HOND N/A
  • LUNG $18.17
  • P/E Ratio
  • HOND $53.55
  • LUNG N/A
  • Revenue Growth
  • HOND N/A
  • LUNG 19.84
  • 52 Week Low
  • HOND $9.90
  • LUNG $2.50
  • 52 Week High
  • HOND $12.24
  • LUNG $9.37
  • Technical
  • Relative Strength Index (RSI)
  • HOND N/A
  • LUNG 39.07
  • Support Level
  • HOND N/A
  • LUNG $2.62
  • Resistance Level
  • HOND N/A
  • LUNG $2.88
  • Average True Range (ATR)
  • HOND 0.00
  • LUNG 0.17
  • MACD
  • HOND 0.00
  • LUNG 0.05
  • Stochastic Oscillator
  • HOND 0.00
  • LUNG 39.68

About HOND HCM II ACQUISITION CORP

HCM II Acquisition Corp is a blank check company.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: